DCBCI 0901

Drug Profile

DCBCI 0901

Alternative Names: DCBCI0901; MTR 393

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Development Center for Biotechnology
  • Developer Standard Chemical & Pharmaceutical Company
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Oct 2017 Standard Chemical & Pharmaceutical Company terminates a phase I trial for Solid tumours (late-stage disease, second-line therapy or greater) in Taiwan (NCT02151357)
  • 19 Mar 2016 Phase-I development is ongoing in Taiwan
  • 01 Jun 2014 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top